GSA Capital Partners LLP Takes $209,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

GSA Capital Partners LLP bought a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 6,512 shares of the company’s stock, valued at approximately $209,000.

A number of other institutional investors have also recently added to or reduced their stakes in SWTX. Vanguard Group Inc. grew its stake in shares of SpringWorks Therapeutics by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company’s stock worth $321,373,000 after purchasing an additional 492,783 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of SpringWorks Therapeutics by 48.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock valued at $202,318,000 after buying an additional 1,333,892 shares in the last quarter. Maverick Capital Ltd. lifted its position in shares of SpringWorks Therapeutics by 36.3% during the 2nd quarter. Maverick Capital Ltd. now owns 2,600,524 shares of the company’s stock valued at $97,962,000 after acquiring an additional 691,894 shares during the last quarter. Fiera Capital Corp boosted its stake in shares of SpringWorks Therapeutics by 41.4% during the 2nd quarter. Fiera Capital Corp now owns 1,297,302 shares of the company’s stock worth $48,869,000 after acquiring an additional 380,027 shares in the last quarter. Finally, Duquesne Family Office LLC acquired a new position in shares of SpringWorks Therapeutics in the 2nd quarter worth $38,475,000.

SpringWorks Therapeutics Stock Up 7.5 %

Shares of NASDAQ:SWTX opened at $39.02 on Monday. The company has a market cap of $2.90 billion, a price-to-earnings ratio of -10.06 and a beta of 0.79. The business has a 50 day moving average price of $32.60 and a 200 day moving average price of $36.74. SpringWorks Therapeutics, Inc. has a twelve month low of $20.19 and a twelve month high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.03. The business had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. SpringWorks Therapeutics’s quarterly revenue was up 4810.0% on a year-over-year basis. During the same quarter last year, the company posted ($1.27) earnings per share. Analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.14 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on SWTX shares. Evercore ISI began coverage on SpringWorks Therapeutics in a research note on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $77.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, November 18th. JPMorgan Chase & Co. raised their target price on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Finally, HC Wainwright decreased their price target on SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research note on Tuesday, November 12th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $67.00.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.